NGM Biopharmaceuticals (NGM) Aktienanalyse

NGM Biopharmaceuticals (NGM) Gesundheitswesen & Pipeline-Uebersicht

NGM Biopharmaceuticals pioneers innovative therapies for liver, metabolic, and retinal diseases, and cancer, leveraging its robust pipeline led by Aldafermin and MK-3655 in Phase IIb trials, and strategic collaborations with Merck, positioning it for significant growth in high-need therapeutic areas.

Investmentthese

NGM Biopharmaceuticals presents a notable research candidate due to its promising pipeline of novel therapeutics targeting significant unmet needs in liver, metabolic, retinal diseases, and cancer. The lead asset, Aldafermin, targeting NASH, a market projected to reach billions of dollars, is a key value driver. Positive Phase IIb clinical trial results for Aldafermin and MK-3655 could serve as significant catalysts, driving stock appreciation. Strategic collaborations with Merck further validate NGM's technology and provide financial support. With a market cap of $0.13 billion and a gross margin of 49.7%, NGM offers substantial upside potential if clinical trials are successful and lead to commercialization.

Basierend auf FMP-Finanzdaten und quantitativer Analyse

Wichtige Highlights

• Market capitalization of $0.13 billion indicates potential for growth if clinical trials are successful.
• Gross margin of 49.7% demonstrates the company's ability to generate revenue from its collaborations and early-stage assets.
• P/E ratio of -0.89 reflects the company's current lack of profitability due to ongoing R&D investments.
• Beta of 1.26 suggests the stock is more volatile than the market average.
• Strategic collaborations with Merck provide financial resources and validation of NGM's technology.

Wettbewerber & Vergleichsunternehmen

Staerken

• Promising pipeline of novel therapeutics.
• Strategic collaborations with Merck.
• Experienced management team.
• Strong intellectual property portfolio.

Schwaechen

• Limited financial resources.
• Dependence on clinical trial outcomes.
• Lack of commercialized products.
• High cash burn rate.

Katalysatoren

• Upcoming: Data readout from Phase IIb clinical trial of Aldafermin for NASH.
• Upcoming: Data readout from Phase IIb clinical trial of MK-3655 for type 2 diabetes and NASH.
• Ongoing: Enrollment and progress in Phase I/II clinical trials of NGM120 and NGM707.
• Ongoing: Advancement of NGM621 through Phase II clinical trials for geographic atrophy.
• Ongoing: Potential for new collaborations and licensing agreements.

Risiken

• Potential: Clinical trial failures could significantly impact the company's valuation.
• Potential: Regulatory delays or rejection of product candidates.
• Ongoing: Competition from other companies developing therapies for the same indications.
• Ongoing: Dependence on collaborations with Merck for financial support and development expertise.
• Potential: Difficulty in raising additional capital to fund ongoing research and development.

Wachstumschancen

• Aldafermin for NASH: The NASH market is expected to grow significantly in the coming years, driven by the rising prevalence of obesity and diabetes. Aldafermin, currently in Phase IIb trials, has the potential to capture a significant share of this market if approved. Success in clinical trials and subsequent commercialization could generate substantial revenue for NGM.
• MK-3655 for Type 2 Diabetes and NASH: MK-3655, also in Phase IIb trials, targets both type 2 diabetes and NASH, offering a dual-pronged approach to these metabolic diseases. The global type 2 diabetes market is substantial, and a successful therapy could provide significant growth opportunities for NGM. Positive clinical data could attract further partnerships and investment.
• NGM621 for Geographic Atrophy: NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials, targets geographic atrophy, a significant unmet need in retinal diseases. The market for geographic atrophy therapies is growing, and successful development of NGM621 could position NGM as a key player in this space. Data readouts from the Phase II trials will be a key catalyst.
• NGM707 for Advanced Solid Tumors: NGM707, a dual antagonist monoclonal antibody, is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors. The oncology market is vast, and successful development of NGM707 could provide significant growth opportunities for NGM. Early clinical data will be crucial in determining the future of this program.
• Strategic Collaborations with Merck: NGM's collaborations with Merck provide access to resources, expertise, and potential revenue streams. These partnerships focus on developing novel medicines for retinal and cardiovascular metabolic (CVM) diseases, including heart failure. Continued success in these collaborations could lead to further expansion of NGM's pipeline and market reach.

Chancen

• Successful clinical trial results.
• Expansion of pipeline through internal discovery and collaborations.
• Partnerships for commercialization of approved therapies.
• Growing market for NASH and other target diseases.

Risiken

• Clinical trial failures.
• Regulatory hurdles.
• Competition from other pharmaceutical and biotechnology companies.
• Patent challenges.

Wettbewerbsvorteile

• Proprietary drug discovery platform.
• Strong intellectual property portfolio.
• Strategic collaborations with major pharmaceutical companies.
• Experienced management team with expertise in drug development.

Ueber NGM

NGM Biopharmaceuticals, Inc., founded in 2007 and headquartered in South San Francisco, California, is a biopharmaceutical company dedicated to discovering and developing novel therapeutics. The company focuses on addressing unmet medical needs in liver and metabolic diseases, retinal diseases, and cancer. NGM's approach involves leveraging its scientific understanding of key biological pathways to create innovative treatments. Their lead product candidate, Aldafermin, is an engineered analog of the human hormone fibroblast growth factor 19 (FGF19), currently in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). Another key asset, MK-3655, is an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, also in Phase IIb clinical trials for the treatment of type 2 diabetes and NASH. NGM is also developing NGM120, an antagonist antibody targeting GFRAL, in Phase I/II trials, NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy, and NGM707, a dual antagonist monoclonal antibody targeting immunoglobulin-like transcript 2 and 4, in Phase I/II trials for advanced solid tumors. The company has established strategic research collaborations, product development, and license agreements with Merck Sharp & Dohme Corp. and Merck & Co., Inc., focusing on developing novel medicines for retinal and cardiovascular metabolic (CVM) diseases, including heart failure.

Was das Unternehmen tut

• Discovers and develops novel therapeutics.
• Focuses on liver and metabolic diseases.
• Develops treatments for retinal diseases.
• Creates therapies for cancer.
• Conducts clinical trials to evaluate product candidates.
• Partners with pharmaceutical companies for research and development.

Geschaeftsmodell

• Develops and out-licenses novel therapeutics.
• Generates revenue through research collaborations and licensing agreements.
• Advances product candidates through clinical trials.
• Seeks partnerships for commercialization of approved therapies.

Branchenkontext

NGM Biopharmaceuticals operates within the biotechnology industry, which is characterized by high growth potential and significant investment in research and development. The industry is driven by the increasing prevalence of chronic diseases, such as NASH, type 2 diabetes, and cancer. The competitive landscape includes established pharmaceutical companies and other biotech firms, such as aTyr Pharma (ATYR), DBTx (DBTX), Graybug Vision (GRAY), Kintara Therapeutics (KNTE), and Pardes Biosciences (PRDS), all vying for market share in these therapeutic areas. NGM differentiates itself through its focus on novel biological pathways and strategic partnerships.

Wichtige Kunden

• Patients with liver diseases, such as NASH.
• Patients with metabolic diseases, such as type 2 diabetes.
• Patients with retinal diseases, such as geographic atrophy.
• Patients with advanced solid tumors.
• Pharmaceutical companies through collaborations and licensing agreements.

Finanzdaten

Chart & Info

Aktuelle Nachrichten

Analystenkonsens

MoonshotScore

NGM Healthcare Aktien-FAQ

Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.

Offizielle Ressourcen

Popular Stocks